NCT02057133 2026-01-26A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has SpreadEli Lilly and CompanyPhase 1 Active not recruiting198 enrolled
NCT02632994 2025-09-29Master Rollover Protocol for Continued Safety Assessment of Study DrugEli Lilly and CompanyAvailable
NCT02784795 2025-08-21A Study of LY3039478 in Participants With Advanced or Metastatic Solid TumorsEli Lilly and CompanyPhase 1 Terminated94 enrolled 28 charts